PE20191045A1 - Anticuerpos anti-il-33 y usos de los mismos - Google Patents
Anticuerpos anti-il-33 y usos de los mismosInfo
- Publication number
- PE20191045A1 PE20191045A1 PE2019000838A PE2019000838A PE20191045A1 PE 20191045 A1 PE20191045 A1 PE 20191045A1 PE 2019000838 A PE2019000838 A PE 2019000838A PE 2019000838 A PE2019000838 A PE 2019000838A PE 20191045 A1 PE20191045 A1 PE 20191045A1
- Authority
- PE
- Peru
- Prior art keywords
- seq
- antibody
- refers
- chain variable
- variable region
- Prior art date
Links
- 102000017761 Interleukin-33 Human genes 0.000 abstract 2
- 108010067003 Interleukin-33 Proteins 0.000 abstract 2
- 206010012438 Dermatitis atopic Diseases 0.000 abstract 1
- 206010039085 Rhinitis allergic Diseases 0.000 abstract 1
- 230000000172 allergic effect Effects 0.000 abstract 1
- 201000010105 allergic rhinitis Diseases 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 201000008937 atopic dermatitis Diseases 0.000 abstract 1
- 208000010668 atopic eczema Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
SE REFIERE A UN ANTICUERPO QUE SE UNE A LA INTERLEUCINA-33 (IL-33) QUE COMPRENDE UNA REGION VARIABLE DE CADENA LIGERA (LCVR) DE SEQ ID NO: 4 Y UNA REGION VARIABLE DE CADENA PESADA (HCVR) DE SEQ ID NO: 3, DONDE DICHO ANTICUERPO COMPRENDE i) DOS LCDR1 DE SEQ ID NO: 16, ii) DOS LCDR2 DE SEQ ID NO: 17, iii) DOS LCDR3 DE SEQ ID NO: 18, iv) DOS HCDR1 DE SEQ ID NO: 13, v) DOS HCDR2 DE SEQ ID NO: 14, Y vi) DOS HCDR3 DE SEQ ID NO: 15. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE DICHO ANTICUERPO, EL CUAL ES UTIL EN EL TRATAMIENTO DE ENFERMEDADES ALERGICAS TAL COMO LA DERMATITIS ATOPICA, ASMA, RINITIS ALERGICA
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662414258P | 2016-10-28 | 2016-10-28 | |
PCT/US2017/058020 WO2018081075A1 (en) | 2016-10-28 | 2017-10-24 | Anti-il-33 antibodies and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20191045A1 true PE20191045A1 (es) | 2019-08-06 |
Family
ID=60263117
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2019000838A PE20191045A1 (es) | 2016-10-28 | 2017-10-24 | Anticuerpos anti-il-33 y usos de los mismos |
Country Status (36)
Country | Link |
---|---|
US (2) | US10501536B2 (es) |
EP (1) | EP3532499B1 (es) |
JP (1) | JP6830533B2 (es) |
KR (1) | KR102266144B1 (es) |
CN (1) | CN109863173B (es) |
AR (1) | AR109948A1 (es) |
AU (1) | AU2017351183B2 (es) |
BR (1) | BR112019005139A2 (es) |
CA (1) | CA3039232C (es) |
CL (1) | CL2019001043A1 (es) |
CO (1) | CO2019003047A2 (es) |
CR (1) | CR20190179A (es) |
CY (1) | CY1124360T1 (es) |
DK (1) | DK3532499T3 (es) |
EA (1) | EA201990778A1 (es) |
EC (1) | ECSP19029758A (es) |
ES (1) | ES2878037T3 (es) |
HR (1) | HRP20211221T1 (es) |
HU (1) | HUE055621T2 (es) |
IL (1) | IL265689B2 (es) |
JO (1) | JOP20190093A1 (es) |
LT (1) | LT3532499T (es) |
MA (1) | MA46619B1 (es) |
MD (1) | MD3532499T2 (es) |
MX (1) | MX2019004863A (es) |
PE (1) | PE20191045A1 (es) |
PH (1) | PH12019500929A1 (es) |
PL (1) | PL3532499T3 (es) |
PT (1) | PT3532499T (es) |
RS (1) | RS62120B1 (es) |
SI (1) | SI3532499T1 (es) |
TN (1) | TN2019000086A1 (es) |
TW (2) | TWI647238B (es) |
UA (1) | UA121293C2 (es) |
WO (1) | WO2018081075A1 (es) |
ZA (1) | ZA201901935B (es) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JOP20190093A1 (ar) * | 2016-10-28 | 2019-04-25 | Lilly Co Eli | أجسام مضادة لـ il-33 واستخداماتها |
EP4045641A1 (en) | 2019-10-15 | 2022-08-24 | Eli Lilly and Company | Recombinantly engineered, lipase/esterase-deficient mammalian cell lines |
CA3158323A1 (en) | 2019-11-04 | 2021-05-14 | Medimmune Limited | Methods of using il-33 antagonists |
KR20220092927A (ko) | 2019-11-04 | 2022-07-04 | 메디뮨 리미티드 | 신장 장애를 치료하기 위한 항 il-33 치료제 |
WO2021180858A1 (en) | 2020-03-13 | 2021-09-16 | Medimmune Limited | Therapeutic methods for the treatment of subjects with risk alelles in il33 |
IL296256A (en) | 2020-03-13 | 2022-11-01 | Genentech Inc | Antibodies against interleukin-33 and uses thereof |
CA3176571A1 (en) | 2020-04-06 | 2021-10-14 | Medimmune Limited | Treating acute respiratory distress syndrome with il-33 axis binding antagonists |
IL297841A (en) | 2020-05-11 | 2023-01-01 | Medimmune Ltd | Formulations of anti-il-33 antibodies |
CN111620948B (zh) * | 2020-06-10 | 2022-04-08 | 南京赛新生物科技有限公司 | 针对il-33的抗体 |
CN113603775B (zh) * | 2021-09-03 | 2022-05-20 | 江苏荃信生物医药股份有限公司 | 抗人白介素-33单克隆抗体及其应用 |
TW202402790A (zh) | 2022-03-25 | 2024-01-16 | 英商梅迪繆思有限公司 | 減少呼吸系統感染之方法 |
WO2024038185A1 (en) | 2022-08-19 | 2024-02-22 | Medimmune Limited | Method of selecting patients for treatment with an il-33 axis antagonist |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ549040A (en) | 2004-02-17 | 2009-07-31 | Schering Corp | Use for interleukin-33 (IL33) and the IL-33 receptor complex |
WO2008132709A1 (en) | 2007-04-26 | 2008-11-06 | Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth, Near Dublin | Products for altering il-33 activity and methods therefor |
CA2686683A1 (en) | 2007-05-18 | 2008-11-27 | Medimmune, Llc | Il-33 in inflammatory disease |
EP2475388B1 (en) | 2009-09-10 | 2017-11-08 | Merck Sharp & Dohme Corp. | Use of il-33 antagonists to treat fibrotic disease |
JP6147674B2 (ja) * | 2011-02-23 | 2017-06-14 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | ヒトil33rに対する抗体およびその使用 |
FR2972006B1 (fr) | 2011-02-24 | 2016-03-25 | Centre Nat Rech Scient | Nouveaux fragments d'il-33 superactifs et leurs utilisations |
US9090694B2 (en) | 2012-04-30 | 2015-07-28 | Janssen Biotech, Inc. | ST2L antibody antagonists |
JO3532B1 (ar) | 2013-03-13 | 2020-07-05 | Regeneron Pharma | الأجسام المضادة لمضاد انترلوكين-33 واستعمالاتها |
BR112016013347B1 (pt) * | 2013-12-26 | 2023-12-12 | Mitsubishi Tanabe Pharma Corporation | Anticorpo monoclonal humano neutralizante anti-il-33, composição farmacêutica, inibidor da expressão de citocinas, molécula de ácido nucleico, vetor, célula bacteriana transgênica, método de produção e uso dos mesmos |
RU2019118984A (ru) * | 2014-01-10 | 2019-08-06 | Анаптисбайо, Инк. | Антитела, направленные против интерлейкина-33 (il-33) |
US10040859B2 (en) * | 2014-04-21 | 2018-08-07 | The Children's Hospital Of Philadelphia | Methods of treating hemophagocytic lymphohistiocytosis with an IL-33 receptor antibody |
EA201791029A1 (ru) | 2014-11-10 | 2017-12-29 | Дженентек, Инк. | Антитела против интерлейкина-33 и их применение |
BR112017020955A2 (pt) | 2015-03-31 | 2018-07-10 | Medimmune Limited | forma de il33, formas mutadas de il33, anticorpos, ensaios e métodos de uso dos mesmos |
SG10202006699XA (en) | 2016-01-14 | 2020-08-28 | Anaptysbio Inc | Inhibition of allergic reaction using an il-33 inhibitor |
JOP20190093A1 (ar) * | 2016-10-28 | 2019-04-25 | Lilly Co Eli | أجسام مضادة لـ il-33 واستخداماتها |
-
2017
- 2017-06-16 JO JOP/2019/0093A patent/JOP20190093A1/ar unknown
- 2017-10-13 TW TW106135006A patent/TWI647238B/zh active
- 2017-10-13 AR ARP170102863A patent/AR109948A1/es unknown
- 2017-10-13 TW TW107143762A patent/TWI676680B/zh active
- 2017-10-24 SI SI201730830T patent/SI3532499T1/sl unknown
- 2017-10-24 PT PT177945938T patent/PT3532499T/pt unknown
- 2017-10-24 UA UAA201903400A patent/UA121293C2/uk unknown
- 2017-10-24 DK DK17794593.8T patent/DK3532499T3/da active
- 2017-10-24 ES ES17794593T patent/ES2878037T3/es active Active
- 2017-10-24 TN TNP/2019/000086A patent/TN2019000086A1/en unknown
- 2017-10-24 PE PE2019000838A patent/PE20191045A1/es unknown
- 2017-10-24 US US15/791,641 patent/US10501536B2/en active Active
- 2017-10-24 KR KR1020197012190A patent/KR102266144B1/ko active IP Right Grant
- 2017-10-24 LT LTEP17794593.8T patent/LT3532499T/lt unknown
- 2017-10-24 PL PL17794593T patent/PL3532499T3/pl unknown
- 2017-10-24 CR CR20190179A patent/CR20190179A/es unknown
- 2017-10-24 AU AU2017351183A patent/AU2017351183B2/en active Active
- 2017-10-24 EA EA201990778A patent/EA201990778A1/ru unknown
- 2017-10-24 MA MA46619A patent/MA46619B1/fr unknown
- 2017-10-24 WO PCT/US2017/058020 patent/WO2018081075A1/en active Application Filing
- 2017-10-24 MD MDE20190980T patent/MD3532499T2/ro unknown
- 2017-10-24 JP JP2019522272A patent/JP6830533B2/ja active Active
- 2017-10-24 MX MX2019004863A patent/MX2019004863A/es unknown
- 2017-10-24 RS RS20210875A patent/RS62120B1/sr unknown
- 2017-10-24 BR BR112019005139A patent/BR112019005139A2/pt unknown
- 2017-10-24 HU HUE17794593A patent/HUE055621T2/hu unknown
- 2017-10-24 EP EP17794593.8A patent/EP3532499B1/en active Active
- 2017-10-24 IL IL265689A patent/IL265689B2/en unknown
- 2017-10-24 CN CN201780065572.XA patent/CN109863173B/zh active Active
- 2017-10-24 CA CA3039232A patent/CA3039232C/en active Active
-
2019
- 2019-03-28 CO CONC2019/0003047A patent/CO2019003047A2/es unknown
- 2019-03-28 ZA ZA201901935A patent/ZA201901935B/en unknown
- 2019-04-16 CL CL2019001043A patent/CL2019001043A1/es unknown
- 2019-04-25 PH PH12019500929A patent/PH12019500929A1/en unknown
- 2019-04-26 EC ECSENADI201929758A patent/ECSP19029758A/es unknown
- 2019-10-25 US US16/663,561 patent/US10913793B2/en active Active
-
2021
- 2021-07-26 CY CY20211100672T patent/CY1124360T1/el unknown
- 2021-07-28 HR HRP20211221TT patent/HRP20211221T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20191045A1 (es) | Anticuerpos anti-il-33 y usos de los mismos | |
PE20200011A1 (es) | ANTICUERPOS ANTI-PEPTIDO BETA AMILOIDE N3pGlu Y SUS USOS | |
PE20181326A1 (es) | Anticuerpos que se unen especificamente a pd-1 y sus usos | |
NZ731735A (en) | Anti-pd-1 antibodies and methods of use thereof | |
PE20200294A1 (es) | Anticuerpos que se unen especificamente a pd-1 y metodos de uso | |
PE20181921A1 (es) | NUEVOS ANTICUERPOS ANTI-SIRPa Y SUS APLICACIONES TERAPEUTICAS | |
PE20150159A1 (es) | Composiciones y metodos para anticuerpos que actuan sobre el factor p | |
PE20181090A1 (es) | Modulacion y tratamiento inmunes de tumores solidos con anticuerpos que se unen especificamente a cd38 | |
MX2019007848A (es) | Anticuerpos anti-pd-1 y usos de los mismos. | |
PE20170903A1 (es) | Conjugados de farmacos con anticuerpos anti-cdh6 | |
PE20210132A1 (es) | Anticuerpos anti-cd3 y usos de estos | |
PE20141147A1 (es) | Anticuerpos a pcsk9 y usos de los mismos | |
NZ738979A (en) | Pd-1 antibodies | |
ES2687282T3 (es) | Anticuerpos humanizados ANTI-CD134 (OX40) y sus usos | |
PE20210180A1 (es) | Anticuerpos anti-cd33, anticuerpos biespecificos anti-cd33/anti-cd3 y usos de estos | |
AR110017A1 (es) | Anticuerpos de pd-1 y usos de estos | |
AR110203A1 (es) | Anticuerpos anti-tim-3 para combinación con anticuerpos anti-pd-1 | |
NZ729158A (en) | Anti-ctla4 monoclonal antibody or antigen binding fragment thereof, medicinal composition and use | |
EA035160B9 (ru) | Антитела к st2 и их применение | |
PE20110808A1 (es) | Anticuerpos contra el receptor 3 de tipo toll | |
CU24636B1 (es) | Anticuerpos que reconocen tau en los residuos 257-271 o 320-334 de la seq id no: 1 | |
PE20141151A1 (es) | Proteinas de union al antigeno cd27l | |
NZ628943A (en) | Human antibodies to clostridium difficile toxins | |
NZ603607A (en) | Cgrp antibodies | |
RU2015110981A (ru) | Комбинации и их применение |